

Flavia Jacobs

WORK EXPERIENCE

Medical Oncologist

IRCCS Humanitas Research Hospital [07/11/2023 – 31/12/2024]

City: Rozzano | Country: Italy | Website: <https://www.humanitas.it> | Name of unit or department: Breast Unit

Head Prof. Armando Santoro

Division of Breast Cancer with Prof. Alberto Zambelli.

Activity in Oncology ward, Day Hospital and clinical trials.

Medical Oncologist Resident

IRCCS Humanitas Research Hospital [01/11/2018 – 31/10/2023]

City: Rozzano | Country: Italy | Website: <https://www.humanitas.it>

Cancer Center, IRCCS Humanitas Research Hospital, Humanitas University

Head of department: Prof Armando Santoro

Medical Research Fellow

Institut Jules Bordet [01/06/2022 – 01/06/2023]

City: Brussels | Country: Belgium | Website: <https://www.bordet.be/en> | Name of unit or department: Academic Trials

Promoting Teams - Business or sector: Human health and social work activities

Academic Trials Promoting Teams, Institute Jules Bordet, Bruxelles, Belgium.

Head of Medical Support Team: Dr Evandro De Azambuja

Experience in clinical trial and academic research project

Medical Oncologist Resident

Humanitas Gavazzeni [01/01/2021 – 31/03/2021]

City: Bergamo | Country: Italy | Website: <https://www.gavazzeni.it>

Cancer Center. Head of Department: Dr Giordano Beretta.

COVID Task Force

IRCCS Humanitas Research Hospital [01/03/2020 – 01/05/2021]

City: Rozzano | Country: Italy | Website: <https://www.humanitas.it>

Diagnosis and treatment of SARS-CoV-2 interstitial pneumonia.

Non-invasive ventilation techniques. HUB vaccine administration

Medical Oncologist Resident

Ospedale Vizzolo Predabissi [01/01/2020 – 31/03/2020]

City: Melegnano | Country: Italy | Website: <https://www.asst-melegnano-martesana.it>

Cancer Center. Head of Department: Prof Andrea De Monte

Emergency Medicine Doctor

Hospital "Ospedali Riuniti Villa Sofia-Cervello" [01/11/2017 – 01/11/2018]

City: Palermo | Country: Italy | Website: <https://www.ospedaliriunitipalermo.it>

Immediate medical care and treatment to patients with acute illnesses, injuries, or emergencies.

Medical Research Trainee

Università degli studi di Palermo [01/05/2015 – 01/05/2016]

City: Palermo | Country: Italy | Website: <https://www.unipa.it>

Cellular and Molecular Oncology Laboratory, DICHIRONS Department, UNIPA, Italy

Head of department: Prof Giorgio Stassi

Medical Research Trainee

Ramathibodi Hospital, Mahidol University [01/08/2014 – 01/09/2014]

City: Bangkok | Country: Thailand | Website: <https://www.rama.mahidol.ac.th/en>

Faculty of Science, Ramathibodi Hospital, Mahidol University in Bangkok, Thailand

EDUCATION AND TRAINING

Residency in Medical Oncology

Humanitas University [01/11/2018 – 31/10/2023]

Address: Via Rita Levi Montalcini, 4, 20072 Pieve Emanuele (Italy) | Website: <https://www.hunimed.eu> |

Field(s) of study:

Medical Oncology | Final grade: 70/70 cum laude

Master Degree in Medicine and Surgery

Università degli Studi di Palermo [01/10/2011 – 31/07/2017]

Address: Piazza Marina, 61, 90133 Palermo (Italy) | Website: <https://www.unipa.it> | Field(s) of study: Health and welfare:

Medicine | Final grade: 110/100 cum laude

ERASMUS+ Traineeship with Grant

Università degli Studi di Palermo [10/01/2017 – 01/07/2017]

City: Gdansk | Country: Poland | Website: <https://mug.edu.pl>

Classical High School Diploma

Liceo Classico Internazionale Statale "Giovanni Meli" [01/09/2006 – 10/07/2011]

City: Palermo | Country: Italy | Website: <https://www.liceomeli.edu.it>

LANGUAGE SKILLS

Mother tongue(s): Italian

Other language(s):

English: listening C1 reading C2 writing C1 spoken production C1 spoken interaction C1

French: listening A2 reading A2 writing A1 spoken production A2 spoken interaction A2

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

DIGITAL SKILLS

Microsoft Excel / Microsoft Office / Google Drive / Microsoft Word / Microsoft Powerpoint

CONFERENCES AND ABSTRACTS

[10/12/2024 – 14/12/2024] San Antonio, Texas

Development and Validation of RSC4AI: a machine learning nomogram to predict RSClin results and guide adjuvant treatment of node-negative HR+/HER2- early breast cancer

[10/12/2024 – 14/12/2024] San Antonio, Texas

Exploring treatment options following progression to CDK4/6i in HR+/HER2- advanced breast cancer: a systematic review and network meta-analysis

[07/12/2024 – 10/12/2024] San Diego, California

Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology

[08/11/2024 – 10/11/2024] Roma, Italy

BTRAPP (Behind the Trial Application): An Innovative Digital Tool for Advancing Breast Cancer Clinical Research by Facilitating Information Sharing on Ongoing Trials and Prompt Communication Among Oncologists for Patient Referral

[08/11/2024 – 10/11/2024] Roma, Italy

Facilitators and barriers to switching from intravenous IV to SC delivery of trastuzumab/pertuzumab: perspectives from pts with BC and healthcare professionals (HCPs)

[08/11/2024 – 10/11/2024] Roma, Italy

Pre-existing and Emerging Immune-Mediated Diseases in Breast Cancer Patients Undergoing Cyclin-Dependent Kinases 4/6 Inhibitors Combined with Endocrine Therapy

[08/11/2024 – 10/11/2024] Roma, Italy

Evaluating the Clinical Relevance of MonarchE and NATALEE studies by the application of the eligibility criteria to a Real- World (RW) Early Breast Cancer (eBC) Population

[15/05/2024 – 17/05/2024] Berlin, Germany

Development and Validation of a Machine Learning (ML) Nomogram to Predict RSClin Results and Guide Adjuvant Treatment of Node-negative HR-positive/Human Epidermal Growth Factor Receptor Negative (HER2-) Early Breast Cancer (eBC) in Europe

[15/05/2024 – 17/05/2024] Berlin, Germany

Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced unacceptable toxicity

[10/05/2024] Milan, Italy

Enhancing Prognostic Accuracy in HR-positive/HER2- negative (HR+/HER2-) Early Breast Cancer (BC) Through Artificial Intelligence (AI) Integrated Multimodal Data Analysis

[10/11/2023 – 12/11/2023] Roma, Italy

Maximizing the outcome with Carboplatin (Cb) in early Triple Negative Breast Cancer (eTNBC) undergoing neoadjuvant chemotherapy (NACT): totally worth it?

[10/11/2023 – 12/11/2023] Roma, Italy

A Postbiotic microbiota-stabilizer improves the management of abemaciclib induced diarrhea in breast cancer patients: a pragmatic two arm study

[10/11/2023 – 12/11/2023] Roma, Italy

The sequencing of antibody-drug conjugates (ADCs) in the treatment of metastatic breast cancer (mBC) across published clinical trials

[20/10/2023 – 24/10/2023] Paris, France

Unlocking the potential of circulating miRNAs in predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis

[20/10/2023 – 24/10/2023] Paris, France

Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in BC pts: a pilot application study

[20/10/2023 – 24/10/2023] Paris, France

Progression-free survival (PFS) assessment by local investigators versus blinded independent central review (BICR) in randomized clinical trials (RCTs) in metastatic breast cancer (MBC): Is it really needed?

[02/06/2023 – 06/06/2023] Chicago, USA

Prognostic value of HER2-Low status in breast cancer: a systematic review and meta-analysis

[11/05/2023 – 13/05/2023] Berlin, Germany

Relationship of diarrhea and neutropenia events with outcomes in patients (pts) with metastatic triple negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG): Post hoc analysis from the Phase 3 ASCENT study

[11/05/2023 – 13/05/2023] Berlin, Germany

HER2 low by immunohistochemistry (IHC) and gene expression by qRT-PCR using OncotypeDX

[11/05/2023 – 13/05/2023] Berlin, Germany

The impact of initial tumour response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: an exploratory analysis of the CLEOPATRA trial

[06/12/2022 – 10/12/2022] San Antonio, Texas

Real-world clinical outcome of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

[06/12/2022 – 10/12/2022] San Antonio, Texas

Evaluation of pathologic response and residual tumor cellularity following neo- adjuvant chemotherapy predict prognosis in breast cancer patients

[06/12/2022 – 10/12/2022] San Antonio, Texas

HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors Plus Endocrine Therapy

[15/10/2022] Milano, Italy

Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea: preliminary data

[09/09/2022 – 13/09/2022] Paris, France

Precocious modulation of peripheral blood lymphocytes predicts long-term outcomes in patients with advanced hormone-receptor positive HER2-negative breast cancer treated with CDK4/6 inhibitors (PALMARES)

[14/10/2022 – 16/10/2022] Amsterdam, Netherlands

The relationship among bowel FDG-PET uptake, pathological complete response, and the influence of eating and exercise habits in breast cancer patients undergoing neoadjuvant chemotherapy

[03/05/2022 – 05/05/2022] Berlin, Germany

Brain 18-FDG-PET patterns in early breast cancer subtypes: relationship with headache

[10/09/2021] Milan, Italy

Success rates of guideline based supportive care for abemaciclib induced diarrhoea in advanced breast cancer

PUBLICATIONS

[2024]

Digital Innovations in Breast Cancer Care: Exploring the Potential and Challenges of Digital Therapeutics and Clinical Decision Support Systems

DOI: 10.1177/20552076241288821

[2024]

The i2b2 Temporal Data-Mining Solution for Automated Reconstruction of Different Breast Cancer Patterns of Care over a Decade of Observation

DOI: 10.37871/jbres1757

[2024]

Empowering beyond Pain: Pain Neuroscience Education Interventions in Breast Cancer Survivorship Care

DOI: 10.3390/cancers16162806

[2024]

The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial

DOI: 10.1016/j.clbc.2024.02.012

[2024]

Ovarian Suppression: Early Menopause and Late Effects

DOI: 10.1007/s11864-024-01190-8

[2024]

Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication

DOI: 10.1093/oncolo/oyae004

[2024]

The Impact of Different Patterns of Residual Disease on Long-term Oncological Outcomes in BC Patients Treated with NACT.
DOI: 10.3390/cancers16020376

[2024]

Progression-free survival assessment by blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis
DOI: 10.1016/j.ejca.2023.113478

[2024]

Unveiling the HER2^{low} phenomenon: exploring immunohistochemistry and gene expression to characterise HR⁺positive HER2^{low}negative early breast cancer
DOI: 10.1007/s10549-023-07151-3

[2023]

Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab
DOI: 10.1016/j.critrevonc.2023.104089

[2023]

Opportunities and challenges of Synthetic Data generation in oncology
DOI: 10.1200/CCI.23.00045

[2023]

Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis
DOI: 10.3390/cancers15133424

[2023]

Prognostic value of HER2-Low status in breast cancer: a systematic review and meta-analysis
DOI: 10.1016/j.esmoop.2023.101592

[2023]

Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab
DOI: 10.1016/j.critrevonc.2023.104089

[2023]

Hope and Hype around immunotherapy in Triple-Negative Breast Cancer
DOI: 10.3390/cancers15112933

[2023]

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
DOI: 10.1038/s41523-023-00534-1

[2023]

Clinical Review on Management of Breast Cancer Visceral Crisis
DOI: 10.3390/biomedicines11041083

[2023]

Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients
DOI: 10.1016/j.breast.2023.03.016

[2023]

Sentinel Lymph Node Biopsy in Breast Cancer Patients Undergoing Neo- Adjuvant Chemotherapy: Clinical Experience with Node-Negative and Node-Positive Disease Prior to Systemic Therapy
DOI: 10.3390/cancers15061719

[2023]

Hormone receptor positive/HER2 negative de novo metastatic breast cancer: a true peculiar entity?

DOI: 10.7573/dic.2022-12-2

[2023]

Diarrhea in patients with HR-positive, HER2-negative advanced breast cancer treated with abemaciclib: a real-world study

DOI: 10.3390/jcm1205177

[2023]

Potential role of circulating miRNAs for breast cancer outcome prediction in the neoadjuvant setting: a road to pave

DOI: 10.3390/cancers15051410

[2023]

The relationship among bowel [18]F-FDG PET uptake, pathological complete response, and eating habits in breast cancer patients undergoing neoadjuvant chemotherapy

DOI: 10.3390/nu15010211

[2022]

Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer

<https://doi.org/10.3390/cancers15010148>

[2022]

Loco-regional treatment of the primary tumor does not improve prognosis in de-novo metastatic breast cancer patients undergoing front-line chemotherapy

DOI: 10.3390/cancers14246237

[2022]

HER2-low: where are we?

DOI: 10.1159/000527391

[2022]

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer

DOI: 10.3390/cancers14215467

[2022]

From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds

DOI: 10.3389/fphar.2022.909566

CLINICAL TRIALS

Subinvestigator in EMBER4 trial

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence.

IRCCS Humanitas Research Hospital, Radiotherapy Department, Milan, Italy

Subinvestigator in EUROPA trial

ExclUsive Endocrine Therapy Or Partial Breast Irradiation for Women Aged >70 Years Early Stage Breast Cancer.

IRCCS Humanitas Research Hospital, Radiotherapy Department, Milan, Italy

Subinvestigator in ROSE trial

Noninterventional, multicentre, prospective, cohort study assessing the quality of life and hormonal levels in premenopausal patients with hormone receptor-positive and her2-negative early breast cancer in Italy.

IRCCS Humanitas Research Hospital, Radiotherapy Department, Milan, Italy

Medical Research Fellow working in the Medical Team of Impassion030 Trial

A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti-PDL1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer". Protocol number: BIG 6-05/AFT-27/WO39391.
Principal Investigator: M Ignatiadis, MD.
Sponsor: F. Hoffmann-La Roche Ltd.
Clinical Trial Supporting Unit at Institut Jules Bordet

Medical Research Fellow working in the Medical Team of AURORA Trial

Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. The AURORA PROGRAM". Protocol number: BIG1-14.
Principal Investigator: Martine Piccart, MD, PhD.
Sponsor: F Breast International Group (BIG a.i.s.b.l).
Clinical Trial Supporting Unit at Institut Jules Bordet

Medical Research Fellow working in the Medical Team of AURA Trial

Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers". Protocol number: IJB-AURA-ODN-004.
Principal Investigator: Nieves Martinez Chanzá, MD.
Sponsor: Institut Jules Bordet.
Clinical Trial Supporting Unit at Institut Jules Bordet

Subinvestigator in RIMNAC study

Analysis of combined assessment of Radiomics pattern in [18]F-FDG-PET/CT, Immunogenic Cell Death induction and Microbiota in the prediction of response to NeoAdjuvant Chemotherapy in breast cancer patients: a proof-of-concept study.
IRCSS Humanitas Research Hospital, Cancer Center, Milan, Italy

HONOURS AND AWARDS

[15/10/2022]

Best Oral Presentation: "Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea: preliminary data"
Spazio Nutrizione - XIII edizione, Milan, Italy

NETWORKS AND MEMBERSHIPS

ESMO Member
AIOM member

CONGRESSES

[10/12/2024 – 14/12/2024]

San Antonio Breast Cancer Symposium, San Antonio, Texas, USA

[08/11/2024 – 10/11/2024]

AIOM 2024, Rome, Italy

[13/09/2024 – 17/09/2024]

ESMO 2024, Barcelona, Spain

[15/05/2024 – 17/05/2024]

ESMO Breast 2024, Berlin, Germany

[09/05/2024]

Artificial Intelligence for Oncology, Milan, Italy

[08/04/2024 – 09/04/2024]

Atelier di Oncologia, Villa Verganti Veronesi, Inveruno, Italy

[12/01/2024 – 13/01/2024]

Back from SanAntonio Breast Cancer, Genova, Italy

[22/11/2023 – 23/11/2023]

REALness, Rome, Italy

[10/10/2023 – 12/10/2023]

AIOM 2023, Rome, Italy

[20/10/2023 – 24/10/2023]

ESMO 2023, Paris, France

[23/06/2023 – 24/06/2023]

Post-ASCO Meeting for Belgium and Luxembourg and Satellite Symposium, Belgium

[11/05/2023 – 13/05/2023]

ESMO Breast Cancer, Berlin, Germany

[03/02/2023 – 04/02/2023]

25th Annual BSMO meeting 2023, Hasselt, Belgium

[14/10/2022 – 15/10/2022]

Spazio Nutrizione - XIII edizione, Milano, Italy

[03/05/2022 – 05/05/2022]

ESMO Breast 2022, Berlin, Germany

[29/04/2022 – 30/04/2022]

Dive: into new horizon, Rome, Italy